

<b>NCT ID</b>	NCT02453620
<b>Title</b>	Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-05-25
<b>Location</b>	California, United States Connecticut, United States Maryland, United States Pennsylvania, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT02343991
<b>Title</b>	Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound
<b>Phase</b>	Not Applicable
<b>Date Added</b>	2015-01-22
<b>Location</b>	Canada
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Transcranial ExABlate
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03170960
<b>Title</b>	Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2017-05-31

<b>Location</b>	Arizona, United States
	California, United States
	Colorado, United States
	Connecticut, United States
	District of Columbia, United States
	Florida, United States
	Georgia, United States
	Illinois, United States
	Kansas, United States
	Kentucky, United States
	Louisiana, United States
	Massachusetts, United States
	Michigan, United States
	Minnesota, United States
	Missouri, United States
	Nebraska, United States
	Nevada, United States
	New Jersey, United States
	New York, United States
	Ohio, United States
	Oklahoma, United States
	Oregon, United States
	Pennsylvania, United States
	South Carolina, United States
	Texas, United States
	Utah, United States
	Virginia, United States
	Australia
	Belgium
	France
	Germany
	Italy
	Netherlands
	Spain
	United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Atezolizumab, Cabozantinib
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03600883
<b>Title</b>	A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreakK 100)
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2018-07-26

<b>Location</b>	California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Indiana, United States Maryland, United States Massachusetts, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Brazil Canada France Germany Greece Hungary Japan Portugal Romania South Korea Spain Switzerland
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Anti PD-1/L1, Midazolam, Sotorasib
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02668770
<b>Title</b>	Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
<b>Phase</b>	Phase 1
<b>Date Added</b>	2016-01-29
<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Ipilimumab, MGN1703
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02285816
<b>Title</b>	MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2014-11-07
<b>Location</b>	Canada

<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	AdMA3, MG1MA3
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03865082
<b>Title</b>	Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-03-06
<b>Location</b>	Arizona, United States California, United States Texas, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Ipilimumab, Nivolumab, Tilsotolimod, Opdivo, Yervoy
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03366155
<b>Title</b>	Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
<b>Phase</b>	Phase 2
<b>Date Added</b>	2017-12-08
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	5FU, cetuximab, FUDR-Dex, Irinotecan, Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter, OneRNA, oxaliplatin, panitumumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT04111458
<b>Title</b>	A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-10-01
<b>Location</b>	Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Germany Netherlands
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	BI 1701963, Trametinib
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04575922
<b>Title</b>	Nivolumab+Ipilimumab+RT in MSS mCRC
<b>Phase</b>	Phase 2

<b>Date Added</b>	2020-10-05
<b>Location</b>	Massachusetts, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Ipilimumab, Nivolumab
<b>Tags</b>	MSS/ MMRp